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Please cite this article as: Niccolò Lombardi PharmD, PhD , Giada Crescioli PharmD ,
Monica Simonetti MSc , Ettore Marconi PharmD , Alfredo Vannacci MD, PhD ,
Alessandra Bettiol MSc, PhD , Damiano Parretti MD , Claudio Cricelli MD ,
Francesco Lapi PharmD, PhD , Adherence to Triple-Free-Drug Combination Therapies among
Patients with Cardiovascular Disease, The American Journal of Cardiology (2020), doi:
https://doi.org/10.1016/j.amjcard.2020.01.036
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Inc.
1 
 
Adherence to Triple-Free-Drug Combination Therapies among Patients with 
Cardiovascular Disease 
 
Running head: Adherence to triple free drug combination therapies in primary care 
Affiliations: Niccolò Lombardi, PharmD PhD
a*
; Giada Crescioli, PharmD
a*





; Alfredo Vannacci, MD PhDa; Alessandra Bettiol, MSc PhDa; Damiano 
Parretti, MD
c
; Claudio Cricelli, MD
c
; Francesco Lapi, PharmD PhD
b  
* 
These authors contributed equally to this work 
a) Department of Neurosciences, Psychology, Drug Research and Child Health, Section of 
Pharmacology and Toxicology, University of Florence, Florence, Italy.  
b) Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy. 
c) Italian College of General Practitioners and Primary Care, Florence, Italy. 
Corresponding author: 
Francesco Lapi, PharmD PhD 
Health Search, Italian College of General Practitioners and Primary Care  
Via del Sansovino, 179- 50142 - Florence, Italy 
Phone number: +39 055494900 or +39 3402648088 
Fax: +39 055494900 
Email address: lapi.francesco@simg.it 
 
Conflict of Interest: FL and EM provided consultancies in protocol preparation for epidemiological 
studies and data analyses for Bayer, Alfa Sigma, and IBSA. DP and CC provided clinical 
consultancies for Bayer, Alfa Sigma, IBSA, and Teva. The other authors declare that they have no 
conflicts of interest to disclose. 
Acknowledgements: This work was supported by Servier. 
Role of funding: The funder of the study had no role in: study design, or collection, analysis, and 
interpretation of data, or writing the manuscript or decision to submit.  




Combination therapies are often needed to modify the concomitant risk factors for cardiovascular 
disease (CVD). Non-adherence to cardiovascular medications is a relevant concern, especially in 
polytherapy. We conducted a population-based, cohort study with the aim of quantifying the level of 
non-adherence and its related determinants in patients exposed to free three-drug combination 
therapies, namely concurrent use of angiotensin-converting-enzyme inhibitor (ACEi), calcium channel 
blockers (CCBs), and statins or of ACEi, statins, and low-dose aspirin. Within Health Search 
Database, we selected a cohort of adult patients concurrently prescribed with ACEi, CCBs, and statin, 
as well as those prescribed with ACEi, statins and low-dose aspirin, from the 1
st
 January 2002 to the 
31
st
 December 2014. Non-adherent patients were concurrent users of triple free pill regimen with a 
proportion of days covered (PDC) <80% during 1-year follow-up; demographics and clinical 
determinants of 1-year non-adherence were identified by multivariate logistic regression. We found 
that more than half of patients prescribed with triple free drug combination therapy with ACEi plus 
CCB plus statins or ACEi plus statins plus low-dose aspirin, were found to be non-adherent to these 
treatments. Males and patients at high/very-high cardiovascular risk were more likely to be adherent, 
while depression and atrial fibrillation were associated with non-adherence. Our findings indicate that 
sex, cardiovascular risk, presence of atrial fibrillation and depression can influence adherence to 
polytherapy. In conclusion, given that patients suffering from multiple cardiovascular risk factors are 
at higher risk of fatal events, strategies are needed to improve medication adherence to combination 
therapies.  
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Cardiovascular diseases (CVD) are the major cause of disability and death in Western countries, and 
their related epidemiological burden is also growing in developing countries. 
1
 CVD continues to be a 
global epidemic, as obesity, sedentary lifestyle and diabetes mellitus are becoming increasingly 
common. Furthermore, the underuse of cardiovascular medications is still a relevant concern. 
2
 All 
these issues need to be considered in the light of the growing aging of population. Namely, more than 
60% of older adults suffer from at least two or more chronic diseases. Among them, CVD were the 
most common conditions. 
3
 In this context, the cardiovascular triple free pill combination therapy has 
already demonstrated its effectiveness in preventing CVD acting on different and concomitant risk 
factors, such as hypertension, hyperlipidemia and/or platelets aggregation.
4,5
 However, regimen 
complexity is known to contribute to poor adherence. 
6
 One of the biggest lacks of clarity on multiple-
pill use for CVD prevention is associated to the poor knowledge of demographic and clinical 
determinants related to non-adherence. Given this background, this study was conducted to assess 
adherence levels in patients treated with triple free drug combinations, namely angiotensin-converting-
enzyme inhibitor (ACEi) plus calcium channel blocker (CCB) plus statins and ACEi plus statins plus 
low-dose aspirin and to identify the determinants of non-adherence to these combination therapies. 
Methods  
We used the Health Search Database (HSD), a longitudinal observational database established 
in 1998 by the Italian College of General Practitioners and Primary Care, containing the electronic 
patient records from approximately 1,000 general practitioners (GPs) homogeneously distributed 
across Italy. Computer-based patient records collected by a selected group of 800 GPs, who met 
standard quality criteria regarding the levels of data entry (i.e. levels of coding, prevalence of selected 
diseases, rates of mortality, and years of recording), were included in the present study. These GPs 
covered almost 1 million patients, and were geographically distributed to include patients 
representative of the whole Italian population and to ensure the completeness and consistency of 
medical records. Records consisted of demographic details; medical information, such as diagnoses, 
drugs and diagnostic test prescriptions; specialist referrals; life-style characteristics and all-cause 
mortality. These data were linked through a unique anonymous code. All diagnoses were coded 
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according to the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-
CM). To complement the coded diagnoses, GPs are enabled to add free text. Information on drug 
prescriptions includes the name of the prescribed drug (i.e., active substance and/or brand name), the 
dosage instruction (i.e. the Prescribed Daily Dosage: PDD) the correspondent Anatomical Therapeutic 
Chemical (ATC) code along with the related Defined daily dose (DDD), the date of prescription, and 
number of days’ supply. The ATC/DDD is a validated classification system from the World Health 
Organization (WHO), considered the standard reference for coding medications in several countries. 
Every prescription was associated with specific diagnoses (i.e. indication of use). A number of 
epidemiological studies have been conducted using HSD.
7,8
 Furthermore, HSD collaborates with other 




We formed two study cohorts identifying all patients aged 18 years or older, prescribed with 
free combinations of ACEi (ATC codes: C09A*; C09BB*) plus CCB (ATC codes: C08*) plus statin 
(ATC codes: C10A*), or ACEi plus statin plus low-dose aspirin (ATC: B01AC06), from the 1
st
 
January 2002 to the 31
st
 December 2014. For each medication class, we adopted PDD to identify the 
related dosages. As such, the overall prescribed amount (i.e. in mgs) was divided by the related PDD 
to provide duration (days) for each prescription. For the identification of triple free pill users eligible 
for calculation of adherence, an overlapping prescription was operationally defined as a prescription 
for 1 of the 3 components before or on the run-out date (prescription date plus days of supply) of the 
other 2 components. When fixed combinations were identified, an overlapping prescription was 
operationally defined as a prescription for 1 of the 2 components (including a fixed combination) 
before or on the run-out date (prescription date plus days of supply) of the other components.
10
 A 
patient was therefore considered exposed to triple free pill regimen whenever the concurrent use of 
the three components covered a minimum period of 60 days.
11
 The start date of this 60-day period was 
defined as the study index date. Patients were followed up until the occurrence of one of the following 
events (whichever came first): death, end of the first year of follow-up, end of registration data with 
his/her GPs, end of data availability (31
st
 December 2015). Patients with less than 1-year follow-up 
were excluded. 
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Adherence to triple free drug combination was calculated as proportion of days covered 
(PDC), which is obtained by dividing the cumulative days of medications use by the length of follow 
up. A PDC <80% was adopted to define patients as non-adherent to three-pill regimen. To identify the 
determinants of non-adherence to triple free drug combination therapy, patients’ characteristics were 
assessed before or on the index date. Namely, we used the cardiovascular risk staging defined as 
mean/moderate (<5%), high (5% and <10%), and very high risk (10%) according to the SCORE 
algorithm.
12
 This method adopts a Weibull model which includes the patient’s age, total cholesterol 
(TC), blood pressure (BP) and smoking, in women and men taken separately. The TC and BP values 
were defined in the year preceding the index date. The last registration of smoking habits was 
identified in the entire available period preceding the index date. The former smokers were considered 
as non-smokers. The SCORE algorithm was applied to patients in primary prevention, such as those 
with no prior cardiovascular event or other related conditions. Furthermore, patients with high 
cardiovascular risk were identified considering the following variables: i) type 2 diabetes with no 
complications, neither other cardiovascular risk factors such as low-density lipoprotein cholesterol 
(LDL-C) >130 mg/dL, current smoking, obesity (ICD-9-CM codes or body mass index ≥30 kg/m
2
 
(last measurement in year preceding or on the entry date or the registration of ICD-9-CM codes)); ii) 
metabolic syndrome; iii) familial hypercholesterolemia (ICD-9-CM codes coupled with the term 
familiar * in the code description); iv) other familial dyslipidemia (ICD-9-CM codes coupled with the 
term familiar*); v) hypertension (systolic blood pressure 140 mmHg or diastolic blood pressure 90 
mmHg being registered in the year preceding or on the entry date); vi) moderate chronic kidney failure 
(glomerular filtration rate [GFR] ranging 30-59 mL/min/1.73 m
2
 (last measurement before or on the 
entry date)). Patients with very-high cardiovascular risk were identified considering the presence of 
previous cardiovascular events (i.e. stroke, ischemic cardiomyopathy, peripheral vascular diseases, 
coronary bypass recorded by ICD-9-CM codes during 12 months before or on the index date), severe 
chronic kidney failure (GFR ranging ≤29 mL/min/1.73 m
2
) including dialysis and/or renal 
transplantation or free text “dialysis” or “renal transplant”, and type 2 diabetes with complications or 
other cardiovascular risk factors such as LDL-C >130 mg/dL, current smoking, obesity (last 
measurement in year preceding or on the entry date and or the registration of ICD-9-CM codes). Other 
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comorbidities examined as candidate determinants included diagnosis of heart failure; atrial 
fibrillation; and depression; being recorded by ICD-9-CM codes in the entire period preceding or on 
the index date. 
We performed descriptive statistics for continuous (mean (SD)), median (IQR) and categorical 
values (N and (%)). Univariate and multivariate logistic regressions were used to evaluate candidate 
determinants of non-adherence. Odds Ratio (OR) and related 95% Confidence Intervals (95% CI) 
were the measure of association. The selection of determinants was conducted using a stepwise 
approach according to a backward selection method by setting p-values to 0.10 and 0.15 for entering 
and exiting variables, respectively.  
We conducted three sensitivity analyses to verify the robustness of the results. Firstly, the 
overlaps criteria and gaps (i.e. “grace period”) between two prescribing cycles were varied from 60 to 
90 and 30 days. Secondly, considering the effect of socio-economic conditions on medication 
adherence, we adopted the official estimates of the Italian National Institute of Statistics (ISTAT) on 
the average salary (hourly rate, €) which is provided by ISTAT according age class (15-29; 30-49; 
≥50), gender and geographic location (north-west, north-east, central, south and Island), to infer the 
effect of economic conditions on medications adherence 
13
. Thirdly, in order to evaluate a possible 
association between medication adherence to ACEi/CCBs/statins and ACEi/statins/low-dose aspirin 
combination therapies, we adjusted the model for the year of index date.  
All statistical analyses were performed using the software STATA version 13 (Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP). This was a retrospective observational 
study, for which the approval by the Ethics Committee is not required (GU n. 76 March 31, 2008). All 
procedures performed in studies involving human participants were in accordance with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards. 
Results 
Overall, we identified 6,302 patients exposed to triple free drug combinations of ACEi plus 
CCBs plus statins (2.7%; among patients being prescribed with at least one of the medications forming 
the combination, n= 235,138) and 15,918 (6.7%; among patients being prescribed with at least one of 
the medications forming the combination, n= 237,892) patients exposed to triple free drug 
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combinations of ACEi plus CCBs plus statins and ACEi plus statin plus low-dose aspirin, respectively 
(Table 1). Most of them (>55%) were male and older than 45 years. Patients prescribed with 
ACEi/CCBs/statins were a little older than patients prescribed with ACEi/statins/low-dose aspirin. On 
average, patients reached the two different triple free drug combinations after 3.9 and 3.2 years, 
cumulating 314.5 (±352.3) and 294.1 (±307.4) days of exposure, respectively. As shown by SDs 
values, duration of use was featured by high variability. 
Among patients eligible to calculation of adherence, 6,176 and 15,600 patients were exposed 
to ACEi/CCBs/statins and ACEi/statins/low-dose aspirin, respectively, with comparable 
characteristics in terms of sex and age (Table 2). Overall, 52.1% and 50.6% of patients were non-
adherent to triple free combination therapy for ACEi/CCBs/statins and ACEi/statins/low-dose aspirin, 
respectively. On average, patients cumulated 257.9 (±102.0) and 263.8 (±96.5) days of exposure, for 
ACEi/CCBs/statins and ACEi/statins/low-dose aspirin use, respectively. In this context, we observed a 
high variability in terms of duration of use. For what concerns the concurrent treatments, 39.2% and 
32.9% were those patients prescribed with more than five medications in ACEi/CCBs/statins and 
ACEi/statins/low-dose aspirin group, respectively. In particular, regarding ACEi/CCBs/statins group, 
43.1% (95% CI 41.3 – 44.8) of non-adherent and 35.3% (95% CI 33.5 – 36.9) of adherent patients 
were prescribed with more than five medications. Similarly, considering non-adherent patients to 
ACEi/statins/low-dose aspirin combination, 36% (95% CI 34.95 – 37.1) and 29.9% (95% CI 28.9 – 
30.9) of them resulted co-exposed with more than five medication. For what concerns the average 
number of pills being prescribed besides triple free drug combinations, 1,416.9 pills per year (95% CI 
1,393 – 1,440.8) and 1,308.7 pills per year [95% CI 1,294.3 – 1,323.0) were prescribed in addition to 
ACEi/CCBs/statins and ACEi/statins/low-dose aspirin combination, respectively. Based on 95% CIs 
overlaps, no difference was found considering adherent and non-adherent patients exposed to 
ACEi/CCBs/statins (Non-adherent: 1,402.8 (95% CI 1,368.9 – 1,436.6) vs. Adherent: 1432.3 (95% CI 
1,398.5 – 1,465.9)) and ACEi/statins/low-dose aspirin ((Non-adherent: 1,306.3 (95% CI 1,285.8 – 
1,326.7) vs. Adherent: 1,311.2 (95% CI 1,290.9– 1,331.4)). There was no substantial difference 
between ACEi/CCBs/statins and ACEi/statins/low-dose aspirin group in terms of patients’ clinical 
characteristics. Namely, patients were similarly distributed across CV risk strata, with the highest 
percentage in very-high cardiovascular risk (70.1% vs. 73.4%). Differently, a slightly higher 
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prevalence was observed for atrial fibrillation (6.4% vs. 4.5%) and depression (7.3% vs. 6.8%) in 
ACEi/CCBs/statins compared to ACEi/statins/low-dose aspirin.  
Table 3 reported predictors of adherence to triple free drug combination therapy being 
investigated through ACEi/CCBs/statins group. In particular, males resulted significantly more 
adherent than females (greater than 27%), while no relation was found considering age. High and 
very-high cardiovascular risk were significantly associated with greater adherence ((high risk: OR: 
1.35 95% CI (1.06 - 1.72); very-high risk: OR: 1.34 95% CI (1.06 - 1.68)). Similar results were 
obtained for the other triple free drug combination (ACEi/statins/low-dose aspirin). In addition, these 
patients resulted significantly less adherent when suffering from atrial fibrillation (lower than 18%) 
and depression (lower than 15%) (Table 4).  
The results of sensitivity analysis, considering two different time-windows criteria to define 
overlaps and gaps between two prescribing cycles (i.e. from 60 to 90 and 30 days), showed no 
substantial difference from the primary analyses. As expected, the results indicated a longer and 
shorter duration of concurrent medications use adopting 30- and 90-day time-windows, respectively 
(Supplementary Table 1 and Table 2). In the second sensitivity analysis, evaluating predictors of 
adherence to triple free drug combinations for ACEi/CCBs/statins, we found that a 1-unit (1 €) 
increase for the hourly rate was significantly associated with greater adherence (OR: 1.14 95% CI 
(1.08 - 1.19)). A similar trend was obtained for the other triple free drug combination 
(ACEi/statins/low-dose aspirin) although we found a non-significant association ((OR: 1.07 95% CI 
(0.95 - 1.20)). Finally, adjusting the model for the year of index date (i.e., index data ≤2004 as 
reference category), we found growing ORs for medications adherence over the study years for 
ACEi/CCBs/statins group (OR: 1.16 95% CI (0.98 - 1.37), OR 1.24 95% CI (1.06 - 1.45), OR: 1.14 
95% CI (0.98 - 1.32) for index date between 2005 and 2007, between 2008 and 2010, ≥2011, 
respectively) and ACEi/statins/low-dose aspirin group (OR: 1.27 95% CI (1.13 - 1.42), OR 1.39 95% 
CI (1.25 - 1.54), OR: 1.01 95% CI (0.92 - 1.12) for index date between 2005 and 2007, between 2008 
and 2010, ≥2011, respectively), although no significant trend was found. 
 Discussion 
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We conducted a real-world retrospective cohort study aimed to quantify the level of adherence 
and its determinants, for patients exposed to two triple free drug regimens in primary care; namely, 
ACEi/CCBs/statins and ACEi/statins/low-dose aspirin combination. Our results indicated that 52.1% 
and 50.6% of patients were non-adherent to ACEi/CCBs/statins and ACEi/statins/low-dose aspirin, 
respectively. These results confirm that non-adherence is one of the most important hurdles to achieve 
effectiveness in preventing CVD. Our evidence is consistent with those reported by the WHO, which 
estimates that the prevalence of non-adherence to antihypertensive medications ranges between 30% 
to 50% 
14
. Similar findings have been obtained considering a recent systematic review and meta-
analysis which established that 45% of patients were non-adherent to antihypertensive medications 
15
. 
A good adherence was associated with a reduction in hospitalization for myocardial infarction (MI), 
stroke, and hospitalization for heart failure.
16
 As reported in a recent systematic review and meta-
analysis absolute risk differences for any CVD associated with poor medication adherence were 13 
cases for any vascular medication, 9 cases for statins and 13 cases for antihypertensive agents, per 
100,000 individuals per year 
17
.  
Adherence to medication could be influenced by multiple interrelating factors. In the last 
decades, several works have been published concerning the variables associated with non-adherence to 
cardiovascular medications. For example, Lemstra and Alsabbagh performed a meta-analysis of cohort 
studies providing estimates of risk indicators associated with non-adherence to antihypertensive 
medications 
18
. They identifying nine variables: diuretics in comparison to ACEi and angiotensin 
receptor blockers (ARBs) and CCBs, ACEi in comparison to ARBs, CCBs in comparison to ARBs, 
those with depression or using antidepressants, not having diabetes, and a lower socioeconomic status. 
In our setting, we found that male sex and high/very high cardiovascular risk were determinants of 
adherence to ACEi/CCBs/statins and ACEi/statins/low-dose aspirin therapy. On the contrary, 
depression and atrial fibrillation were associated with non-adherence. These findings are consistent 
with those already published in several observational studies. In fact, differences in drug utilization 
were observed for all ages and medication types 
19
. In general, women were less likely to be adherent 
in their use of chronic medications than men. A meta-analysis found that gender has an impact on 
adherence to cardiovascular medications, demonstrating that women had 10 percent greater odds of 
being non-adherent than men 
20
. In terms of cardiovascular risk and adherence levels, our results are 
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fairly consistent with data published by Poluzzi et al 
21
. In this study, patients at the highest 
cardiovascular risk, requiring a stricter adherence to therapy, showed a higher rate of medications 
daily coverage compared to patients at lower cardiovascular risk. Our findings confirm the role of 
depression as a cause of non-adherence, in particular those treated for CVD, who could forget/decide 
to skip taking their medications 
22
. Indeed, around 50% of patients with CVD experienced at least one 
major or minor depression episode. The association between depression and non-adherence may be 
driven by a third factor, such as cognitive decline, which is frequently associated with depression and 
it has been associated with non-adherence as well 
23
. Given that, our cohort was mainly formed by 
elderly patients, the cognitive decline might have been a relevant component in those with depression. 
Several studies described medications’ underuse in patients with atrial fibrillation. As reported 
by Brieger et al.,
24
, evaluating patients’ adherence for secondary prevention of acute coronary 
syndrome after the first 6 months of follow up, atrial fibrillation were independently associated with 
lower likelihood of adherence. Furthermore, the use of anticoagulants in patients with atrial fibrillation 
might have enhanced non-adherence to other medications because of the complex therapeutic 
regimens of anticoagulants as well as the clinical relevance of drug-drug interactions.  
In our study, we identified a lack of effect of age as determinant for adherence levels. This 
result differs from what has been observed in prior studies on adherence to cardiovascular medications 
25
. Nevertheless, our exposure categories were featured by similar health status given with the use of 
triple combinations ACEi/CCBs/statins or ACEi/statins/low-dose aspirin which were indicators of 
similar clinical complexity per se. Not surprisingly, more than 70% of patients were at very high 
cardiovascular risk at the baseline.   
 Our findings might support GPs to identify patients at risk of non-adherence knowing their 
demographic and clinical features. By doing so, specific software applications, such as clinical 
decision support systems (CDSS), might be developed to early identify patients at-risk of non-
adherence in the first year of therapy. This approach should be easily implemented in primary care 
given the current and broad availability of electronic medical care charts which are mandatory for GP 
to provide patients care (D.M. 4 March 2009 (G.U. n. 146 del 26 June 2009); DPCM 26 March 2008 
(G.U. 28 May 2008, n. 124). Through CDSS, GPs could choose the best strategy aimed to minimize 
the burden of non-adherence. They comprise the use of education materials on the relevance of 
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medication adherence, the advice on the use of supporting tools (i.e., mobile application), a greater 
interaction with pharmacists and nurses, as well as the simplification of drug regimens through the use 
of fixed combination pills (i.e., polypill), whenever patients are on target with free combinations 
4,10,26,27
. 
As showed in a recent meta-analysis, polypill-based care was associated with an improve in 
medication adherence and this strategy could contribute significantly to the WHO goal of reducing 
CVD in the next years 
28
. Indeed, the ESC/ESH Guidelines for the management of arterial 
hypertension suggests that the treatment with polypill may be considered in patients with hypertension 
as substitution therapy 
29
.  
The present study had several strengths. First, the Italian HSD, one of the largest general 
practice databases in Europe, contains reliable information on a large population assisted in primary 
care throughout Italy. All data herein reported result homogenous and country-representative, and can 
provide a deep insight of a real-world clinical setting. Second, in the HSD, information on drug 
exposure is prospectively recorded by GPs, thereby minimizing any recall bias.  
This study has some limitations as well. As in other database studies evaluating medication 
adherence, GPs’ prescriptions are used to estimate the measure of adherence. Therefore, we are not 
certain whether patients actually filled and ingested the prescribed medications. However, direct 
comparison with official reports on defined daily dosages (DDDs) for these medication classes 
showed consistent results with ours, so demonstrating no difference between prescribed and dispensed 
amounts. Although HSD does not possess any variable measuring socioeconomic inequalities, we 
adopted the official estimates of ISTAT on the average salary (hourly rate, €) which is provided by 
ISTAT according age class (15-29; 30-49; ≥50), gender and geographic location (north-west, north-
east, central, south and Island). Furthermore, we examined a cohort of elderly patients who shared a 
certain degree of severity, given they were exposed to three concurrent medications. That being said, 
they should be more homogeneous for non-clinical features when compared with general population.  
In conclusion, this study confirms that low medication adherence is one of the most important 
hurdles to overcome for enhancing the medication effectiveness in preventing CVD 
30
. This issue is 
particularly relevant in primary care, being GPs the main prescribers for CVD as well as for other 
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chronic conditions. Our data suggest that, in a real world-setting, strategies should be implemented to 
minimize the burden of non-adherence.  
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Table 1. Characteristics of patients according to type of triple free pill combination: 
ACEi/CCBs/statins and ACEi/statins/low-dose aspirin. 
Characteristics 
ACEi/CCB/statin ACEi/statin/low-dose aspirin 
(N=6,302) (N= 15,918) 
   
Women 2,609 (41.4%) 5,860 (36.8%) 
Men 3,693 (58.6%) 10,058 (63.2%) 
Age (years)   
<45 139 (2.2%) 406 (2.6%) 
45-54 676 (10.7%) 1,932 (12.1%) 
55-64 1,751 (27.8%) 4,416 (27.7%) 
65-74 2,449 (38.9%) 5,859 (36.8%) 
75-84 1,174 (18.6%) 2,982 (18.7%) 
85 113 (1.8%) 323 (2.1%) 
Age (years, mean ± SD) 66.2 ±9.93 65.8 ±10.33 
Time to triple therapy 
(years) 
  
mean ±SD 3.9 ±3.36 3.2 ±3.2 
median 3.06 2.25 
minimum and maximum 0.0-12.83 0-12.87 
p25 – p75 0.9-6.16 0.4-5.28 
Triple therapy duration 
a
   
mean ±SD 314.5 ±352.3 294.1 ±307.4 
median 191.5 191 
minimum and maximum 60 – 4,013 60 – 4,433 




ACEi/CCB/statin ACEi/statin/low-dose aspirin 
(N=6,302) (N= 15,918) 
p25 – p75 130 - 343 134 - 328 
ACEi= angiotensin-converting-enzyme inhibitor; CCB= calcium channel blocker; SD= standard 
deviation. 
a 





Table 2. Characteristics of patients eligible to calculation of adherence to triple free pill 
therapy: ACEi/CCBs/statins and ACEi/statins/low-dose aspirin. 
Characteristics 
ACEi/CCB/statin ACEi/statin/low-dose aspirin 
(N=6,176) (N=15,600) 
Proportion of days covered 
(PDC) 
  
Non-adherent (<80%) 3,217 (52.1%) 7,892 (50.6%) 
Adherent (80%) 2,959 (47.9%) 7,708 (49.4%) 
Women 2,547 (41.2%) 5,716 (36.6%) 
Men 3,629 (58.8%) 9,884 (63.4%) 
Age (years)   
<45 53 (0.8%) 241 (1.5%) 
45-54 408 (6.6%) 1,313 (8.4%) 
55-64 1,314 (21.3%) 3,493 (22.4%) 
65-74 2,287 (37.0%) 5,588 (35.8%) 




ACEi/CCB/statin ACEi/statin/low-dose aspirin 
(N=6,176) (N=15,600) 
75-84 1,785 (29.0%) 4,205 (27.0%) 
85 329 (5.3%) 760 (4.9%) 
Age (years, mean ±SD) 69.8 ±9.8 68.8 ±10.4 
Triple therapy duration 
a
   
mean ±SD 257.9 ±102.0 263.8 ±96.5 
median 283 290 
minimum and maximum 60-365.2 60-365.2 
p25 – p75 165.0 - 362.5 173.0 – 361.0 
Cardiovascular risk   
Mean/moderate 332 (5.4%) 1,016 (6.5%) 
High 1,514 (24.5%) 3,135 (20.1%) 
Very-high 4,330 (70.1%) 11,449 (73.4%) 
Other conditions   
Heart failure 344 (5.6%) 890 (5.7%) 
Atrial fibrillation 398 (6.4%) 701 (4.5%) 
Depression 450 (7.3%) 1,066 (6.8%) 
ACEi= angiotensin-converting-enzyme inhibitor; CCB= calcium channel blocker; SD= standard deviation. 
a 
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Table 3. Determinants of 1-year adherence to triple free pill therapy with ACEi/CCB/statin. 
 OR (95% CI)  
 
Crude Adjusted p-value 
    
Women 1.00 1.00  
Men 1.32 (1.20 - 1.46) 1.27 (1.15 - 1.42) <0.001 
Age (years)    
<45 1.00 1.00  
45-54 0.97 (0.54 -1.71) 1.01 (0.57 -1.79) 0.981 
55-64 0.91 (0.52 -1.58) 0.96 (0.55 -1.67) 0.883 
65-74 0.83 (0.48 -1.43) 0.89 (0.51-1.53) 0.667 
75-84 0.76 (0.44 -1.32) 0.84 (0.48 -1.46) 0.528 
85 0.62 (0.35 -1.11) 0.70 (0.39 -1.26) 0.226 
Cardiovascular risk     
Intermediate/Moderate 1.00 1.00  
High 1.31 (1.03 -1.67) 1.35 (1.06 -1.72) 0.014 
Very-high 1.33 (1.06 -1.67) 1.34 (1.06 -1.68) 0.013 
Other conditions    
Heart failure 0.95 (0.77 -1.19) -  
Atrial fibrillation 0.96 (0.78 -1.18) -  
Depression 0.95 (0.78 -1.15) -  
ACEi= angiotensin-converting-enzyme inhibitor; CCB= calcium channel blocker; CI= confidence interval; OR= 
Odds Ratio; SD= standard deviation. 
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Table 4. Determinants of 1-year adherence to triple free pill therapy with ACEi/statin/low-
dose aspirin. 
 OR (95% CI)  
 
Crude Adjusted p-value 
    
Women 1.00 1.00  
Men 1.20 (1.13 - 1.28) 1.14 (1.06 - 1.22) <0.001 
Age (years)    
<45 1.00 1.00  
45-54 0.97 (0.74 - 1.28) 0.98 (0.74 - 1.29) 0.888 
55-64 0.92 (0.71 - 1.19) 0.94 (0.73 - 1.22) 0.658 
65-74 0.85 (0.66 - 1.11) 0.89 (0.69 - 1.16) 0.384 
75-84 0.77 (0.59 - 0.99) 0.81 (0.62 - 1.05) 0.118 
85 0.74 (0.55 - 0.99) 0.80 (0.60 - 1.08) 0.144 
Cardiovascular risk     
Intermediate/Moderate 1.00 1.00  
High 1.27 (1.1 - 1.46) 1.30 (1.12 - 1.49) <0.001 
Very-high 1.35 (1.18 - 1.53) 1.35 (1.18 - 1.54) <0.001 
Other conditions    
Heart failure 0.86 (0.75 - 0.99) 0.90 (0.78 - 1.03) 0.132 
Atrial fibrillation 0.78 (0.67 - 0.91) 0.82 (0.7 - 0.95) 0.009 
Depression 0.81 (0.72 - 0.92) 0.85 (0.75 - 0.96) 0.011 
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